

Scandion Oncology Q1 2023 - Progressing towards CORIST readouts

Redeye comments on Scandion Oncology's Q1 2023 report, which follows a first quarter where the company delivered PANTAX phase Ib top-line data, which aligned with our expectations. We judge that CORIST part 4 data is the primary catalyst for the company's share in the coming 12-18 months. We do some housekeeping in our model and update our estimates and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Scandion Oncology Q1 2023 - Progressing towards CORIST readouts](#)